

- 24 Email: jandr@stanford.edu
- 25 Phone: +1 650 497 2679

26

27 **Running title:** A rapid pharmacogenomic assay for isoniazid dosing

28

- 29 Summary: This manuscript describes the development and validation of point-of-care multiplex
- 30 pharmacogenomic assay to guide personalized dosing of isoniazid for treatment or prevention of
- 31 tuberculosis.

33 **Abstract**

34 **Rationale:** Standardized weight-based dose of anti-tubercular drugs contributes to a substantial 35 incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug 36 levels achieved. Single nucleotide polymorphisms (SNPs) in the N-acetyltransferase-2 *(NAT2)* 37 gene explain the majority of interindividual pharmacokinetic variability of isoniazid (INH). 38 However, an obstacle to implementing pharmacogenomic-guided dosing is the lack of a point-of-39 care assay.

40 **Objectives:** To develop and test a *NAT2* classification algorithm, validate its performance in 41 predicting isoniazid clearance, and develop a prototype pharmacogenomic assay.

42 **Methods:** We trained random forest models to predict *NAT2* acetylation genotype from 43 unphased SNP data using a global collection of 8,561 phased genomes. We enrolled 48 44 pulmonary TB patients, performed sparse pharmacokinetic sampling, and tested the acetylator 45 prediction algorithm accuracy against estimated INH clearance. We then developed a cartridge-46 based multiplex qPCR assay on the GeneXpert platform and assessed its analytical sensitivity on 47 whole blood samples from healthy individuals.

48 **Measurements and Main Results:** With a 5-SNP model trained on two-thirds of the data 49 (n=5,738), out-of-sample acetylation genotype prediction accuracy on the remaining third 50 (n=2,823) was 100%. Among the 48 TB patients, predicted acetylator types were: 27 (56.2%) 51 slow, 16 (33.3%) intermediate and 5 (10.4%) rapid. INH clearance rates were lowest in predicted 52 slow acetylators (median 19.3 L/hr), moderate in intermediate acetylators (median 41.0 L/hr) and 53 highest in fast acetylators (median 46.7 L/hr). The cartridge-based assay accurately detected all 54 allele patterns directly from 25ul of whole blood.

- 55 **Conclusions:** An automated pharmacogenomic assay on a platform widely used globally for
- 56 tuberculosis diagnosis could enable personalized dosing of isoniazid.
- 57 **Keywords:** tuberculosis; isoniazid; pharmacogenomic; molecular diagnostic; *NAT2*

58

60 **INTRODUCTION**

61 Despite the availability of effective chemotherapeutic regimens for treatment and prevention of 62 tuberculosis, a substantial proportion of patients experience toxicities, fail treatment or develop 63 recurrent disease (1-3). Standardized, weight-based dosing of anti-tuberculosis treatment has 64 been the conventional approach to therapy, despite mounting evidence that inter-individual 65 variability in metabolism leads to highly variable drug levels (4,5). High drug levels are strongly 66 associated with risk of toxicity, while low drug levels are a determinant of treatment failure, slow 67 response, and emergence of drug resistance. Hepatotoxicity is the most common adverse effect, 68 affecting up to 33% of patients receiving standard four-drug therapy (6) and leading to regimen 69 changes in up to 10% of patients (7). This toxicity is associated with increased costs, morbidity, 70 and occasional mortality, particularly among HIV co-infected individuals (8). Additionally, as 71 many as 3% of new tuberculosis cases experience treatment failure, and between 6-10% relapse 72 within 2 years (9,10). Pharmacokinetic variability to a single drug is associated with treatment 73 failure and acquired drug resistance (11,12). One study found that individuals with at least one 74 drug below the recommended AUC threshold had a 14-fold increased risk of poor outcomes (13)

75 More than 50 years after its introduction, isoniazid (INH) remains one of the major first line 76 drugs used to treat active and latent tuberculosis infections (14,15). There has been an increasing 77 number of genetic markers identified that predict metabolism and toxicities from various 78 antimicrobials. INH is among the most well characterized of these, with more than 80% of its 79 pharmacokinetic variability explained by mutations in the gene encoding arylamine N-80 acetyltransferase 2 (NAT2), responsible for its metabolism in the liver (16-18). The primary step 81 in the metabolism of INH is acetylation, catalyzed by the NAT2 enzyme, resulting in the

82 formation of acetyl-INH. The NAT2 enzyme displays genetic polymorphism, and its activity is 83 expressed at highly variable levels. A high correlation between INH acetylator phenotype and 84 seven most frequent SNPs in *NAT2* gene has been demonstrated by several studies (19-22). 85 Individuals can be classified into three phenotypes—rapid, intermediate, and slow acetylators— 86 according to whether they carry polymorphisms on neither, one, or both copies of this gene, 87 respectively. Rapid acetylators typically have the lowest plasma INH concentrations, while slow 88 acetylators have high concentrations (23). A worldwide population survey on *NAT2* acetylation 89 phenotype reported that more than half of the global population are slow or rapid acetylators 90 (18). A meta-analysis of 14 studies, comprising 474 cases and 1446 controls based on *NAT2* 91 polymorphisms found that rapid acetylators are twice as likely to have microbiological failure 92 and acquired drug resistance. Additionally, a significant association has been consistently 93 observed between *NAT2* slow acetylators and the risk of anti-tuberculosis drug-induced liver 94 injury (17). Additional meta-analyses have identified a three- to four-fold increased risk of 95 hepatotoxicity among slow acetylators (24). A randomized trial of pharmacogenomic guided 96 dosing for tuberculosis treatment found that, compared with standard dosing, it reduced 97 hepatotoxicity among slow acetylators and increased treatment response at 8 weeks among rapid 98 acetylators (25)

99

100 Despite this evidence, pharmacogenomic testing and guided treatment has not entered the 101 mainstream of clinical practice for tuberculosis. Few clinical laboratories perform *NAT2* 102 genotyping, which requires detection of multiple polymorphisms and testing for heterozygous 103 allele patterns. Such testing is not widely available in resource-constrained environments where 104 the majority of tuberculosis burden falls. To address this gap, we developed an algorithm from

114 **METHODS**

115 **Datasets**

116 The datasets used to develop the NAT2 classifier was obtained from the IGSR (International

- 117 Genome Sample Resource, 1000 genomes project) and a meta-analysis by Sabbagh et. al (18,
- 118 26). Population information on the combined dataset is provided in **Supplementary Table 1.**

119

120 *NAT2* **acetylator phenotype prediction classifier**

121 Phased genomes from 8,561 individuals were used and haplotypes were labeled based on seven 122 most frequent SNPs (both synonymous and non-synonymous) which are reported to affect the 123 acetylation on INH - rs1801279 (191G>A), rs1041983 (282C>T), rs1801280 (341T>C), 124 rs1799929 (481C>T), rs1799930 (590G>A), rs1208 (803A>G) and rs1799931 (857G>A) (19) in 125 the *NAT2* gene, following an international consensus nomenclature (27). We then constructed an 126 unphased dataset containing only information on whether each sample was wild type for both 127 alleles, homozygous variant for both alleles, or heterozygous. We stratified the dataset by 128 geographic region and then drew a random sample from two-thirds of each stratum for a training 129 set and one third for an out-of-sample test set, to ensure geographic representativeness in the 130 training and test sets. We trained random forest models on the training set using the *caret* 131 package in R and assessed classification performance on the held-out test set. We began with a 7 132 SNP model and eliminated SNPs in sequential models according to the lowest variable 133 importance factor.

134

135 **Ethics statement**

136 The clinical study was approved by the institutional review boards of the Stanford University 137 School of Medicine and Federal University of Grande Dourados. All participants were over the 138 age of 18 and provided written informed consent. For assay optimization and validation on 139 GeneXpert cartridge, anonymized blood samples from healthy individuals were obtained from 140 Stanford blood center.

141

142 **Sample collection**

143 Sputum and plasma samples from 48 newly diagnosed patients with active pulmonary 144 tuberculosis were collected at the Federal University of Grande Dourados, Brazil. All 145 participants were treated with standardized, weight-based doses of isoniazid, rifampicin, 146 pyrazinamide and ethambutol. Plasma samples were collected at 1 hour and 8 hours after the first 147 dose and after 1 hour on day 14. Plasma drug concentrations for isoniazid and acetyl-isoniazid 148 were quantified by high-performance liquid chromatography coupled to tandem mass 149 spectrometry (HPLC-MS) as previously described (28).

150

151 **Pharmacokinetic analysis of INH clearance in tuberculosis patients**

152 The population PK analysis was performed using the non-linear mixed effects modeling 153 approach using NONMEM (version 7.4.3; ICON plc, Gaithersburg, MD, USA), PsN and R-154 based Xpose (version 4.7 and higher) (29,30). One-compartment model with a first-order 155 absorption with a lognormal distribution for inter-individual variability (IIV) on different PK 156 parameter(s) as well as an additive and/or proportional model for the residual error were tested 157 for the base model selection. Mixture models with two or three subpopulations representing 158 different clearance rate were then evaluated. The first-order conditional estimation with 159 interaction method (FOCEI) was applied and the model-building procedure and model selection 160 was based on the log-likelihood criterion (the difference in the minimum OFV between 161 hierarchical models was assumed to be Chi-square distributed with degrees of freedom equal to 162 the difference in the number of parameters between models), goodness-of-fit plots (e.g. relevant 163 residuals against time randomly distributed around zero), and scientific plausibility of the model. 164 Visual predictive check was conducted to evaluate whether the final model with estimated fixed-165 effect parameters and covariates adequately describe data.

166

167 **Sputum processing and host DNA extraction**

168 Spontaneously expectorated sputum samples from confirmed pulmonary tuberculosis patients 169 were collected in 10mL of guanidine thiocyanate (GTC) solution. The samples were needle 170 sheared and centrifuged at 3000 rpm for 30 min. The supernatant was collected in Trizol LS and 171 host DNA was extracted from the supernatant using a manual extraction method described 172 previously (31).

173

174 **Primers and probes for melt curve analysis**

175 We first developed single-plex melt curve assays based on molecular beacon probe chemistry for 176 five NAT2 polymorphisms. Using same primer and probe sequences, we further developed 177 multiplex NAT2-PGx assay compatible on GeneXpert platform. Three sets of primers and five 178 molecular beacon probes spanning the *NAT2* gene were used. Primers and probes were designed 179 using Beacon Designer (Premier Biosoft International, Palo, CA; version 8). A list of primers 180 and probes sequences with their corresponding fluorophores and quenchers is provided in 181 **Supplementary Table 2.**

182 **NAT2-genotyping on pulmonary TB samples**

183 Host genomic DNA extracted from 48 sputum samples from TB positive patients was used to 184 perform single-plex qPCR assays developed in-house. The assays were validated using TaqMan 185 commercial genotyping assays (NAT2 TaqMan® SNP Genotyping Assays, Applied 186 Biosystems). The genotyping was performed on StepOne Plus Real Time PCR (Applied 187 Biosystems). The NAT2-genotypes derived from the assays were used to predict INH acetylator 188 phenotype by our 5-SNP model.

189

190 **Automated NAT2-PGx Multiplex PCR and melt curve analysis**

191 We combined the five single-plex NAT2 melt curve assays validated on TB samples into one 192 and developed a multiplex assay (NAT2-PGx) on the FleXible Cartridge (Flex cart-01, Cepheid) 193 platform. Flex cart allows automated DNA extraction from whole blood followed by PCR 194 amplification and melt curve analysis to detect SNPs in *NAT2* gene in a single run. NAT2-PGx 195 assay was performed on a GeneXpert IV instrument using GeneXpert Dx 4.8 software (Cepheid, 196 Sunnyvale). Briefly, 100ul of whole blood was mixed with 900ul of GeneXpert lysis buffer for 197 whole blood (Cepheid), incubated for 2 min at room temperature and loaded into sample 198 preparation chamber of the flex cart for automated DNA extraction. A 70ul of PCR mastermix 199 was simultaneously loaded in the PCR reaction chamber of the flex cart-01. PCR and melt 200 conditions were optimized using mastermix prepared in house.

201 We validated the multiplex assay on blood samples from 20 healthy individuals. The accuracy of 202 multiplex NAT2-PGx assay in SNP calling was subsequently validated by Sanger sequencing 203 (see methods). We assessed analytical sensitivity of the assay and robustness to input blood 204 volume by performing it on varying volumes of whole blood (200 ul, 100 ul, 50 ul, 25 ul) and

205 comparing the Tm results and standard deviation for each position across blood volumes. 206 Additional details on the qPCR run method and melt curve analysis is provided in an online data 207 supplement.

208

209 **RESULTS**

210 **SNP selection and development of acetylation prediction model**

211 Complete phased data for the seven polymorphisms that define acetylation haplotypes were 212 available for 8,561 individuals from 59 populations. The dataset contains 3,573 (41.7%) 213 individuals with a slow genotype, 3,428 (40.0%) individuals with an intermediate genotype, and 214 1,560 (18.2%) individuals with a rapid genotype (See **Table 1**). The highest proportion of rapid 215 acetylators were in East Asia (40%), and three regions had prevalence of slow acetylator 216 phenotypes over 50% (Central and South Asia, Europe and North Africa). We used these phased 217 allele data to select SNPs for inclusion in an assay measuring unphased SNPs. Using a random 218 forest model trained on two thirds of the data (n=5,738), out-of-sample phenotype prediction 219 accuracy from unphased data on the remaining one third (n=2,823) was 100% for models using 220 7, 6 or 5 SNPs. With 4 SNPs, prediction accuracy was 98.0% (95% CI: 97.4-98.5%), and a 3 221 SNP model had similar performance (98.0%; 95% CI: 97.4-98.4%) (**Table 2**). However, both of 222 these models performed poorly on data from Sub-Saharan Africa (4 SNP model accuracy: 223 82.5%, 95% CI: 78.1-86.4%); 3 SNP model accuracy: 81.3%, 95% CI: 76.8-85.3%). Based on 224 these results, we selected the 5 SNP model (191G>A, 282C>T, 341T>C, 590G>A and 857G>A) 225 to take forward for clinical validation and diagnostic development.

226

227 **Genotype correlation with isoniazid clearance in patients with tuberculosis**

228 We enrolled a cohort of 48 patients with newly diagnosed pulmonary tuberculosis and collected 229 plasma at 1 hour and 8 hours after dose on day 1 and at 1 hour after dose on day 14. To detect 230 five *NAT2* polymorphisms identified by our classifier, we performed single-plex melt curve 231 qPCR assays developed in-house using host DNA extracted from sputum samples. Additionally, 232 we used commercial 7-SNP single-plex genotyping assays and compared the results with 5-SNP 233 single-plex PCR to validate the melt curve accuracy in SNP detection. There was 100% 234 concordance in terms of SNP detection between single-plex melt curve and commercial 7-SNP 235 assays. Of the 48 individuals for whom *NAT2* genotypes were profiled, DNA-probe hybrid 236 melting temperature difference (ΔTm) (°C) between wild-type and mutant alleles for positions 237 191, 282, 341, 590 and 857 were found to be 4.38, 4.04, 2.40, 3.63 and 3.68 respectively. Both 238 mutant and wild type probes had a minimum 2.40°C Tm difference which allowed SNP calling 239 with high accuracy **(Table 3).**

240

241 We further predicted phenotypes from 5-SNP using the algorithm described above as well as a 242 publicly available tool (NAT2Pred) (32), which uses a 6 SNP model that excludes rs1801279 243 (191G>A) and includes other two sites from 7-SNP model- rs1799929 (481C>T) and rs1208 244 (803A>G) when compared with our 5-SNP model. Among the 48 participants, predicted 245 acetylator types from the 5 SNP assay were: 27 (56.2%) slow, 16 (33.3%) intermediate and 5 246 (10.4%) rapid. NAT2Pred classified 4 samples as intermediate that were classified as rapid $(n=1)$ 247 or slow $(n=3)$ by the 5 SNP classifier. Among those classified as slow by the 5 SNP classifier 248 and intermediate by NAT2Pred, acetyl-INH to INH ratios at 8 hours were 0.61, 0.38, 0.41, 249 consistent with slow acetylation (median: 0.76, range 0.36-1.55) rather than intermediate 250 acetylation (median 6.67, range 3.32-22.21) and suggesting misclassification by NAT2Pred. The

251 sample classified as intermediate by NAT2PRed and rapid by the 5 SNP classifier had an acetyl-252 INH to INH ratio of 9.8, which fell between the median values, and within both ranges, for 253 intermediate and rapid acetylators (range 8.09 - ∞) (**Supplementary Table-3**). Phenotypes 254 predicted by the 5 SNP classifier were strongly predictive of INH acetylation and clearance 255 (**Figure 1a and 1b**). INH clearance rates were lowest in slow acetylators (median 19.3 L/hr), 256 moderate in intermediate acetylators (median 41.0 L/hr) and highest in fast acetylators (median 257 46.7 L/hr).

258

259 **Development of an automated pharmacogenomic assay**

260 We validated the NAT2-PGx assay on 20 whole blood samples from healthy individuals. The 261 hands-on time for the cartridge preparation per sample was 5 minutes followed by 140 minutes 262 for overall run that included automated DNA extraction (**Figure 2**). Mutant, wild-type and 263 heterozygous alleles were manually called based on peak patterns and Tm values detected in 264 melt curves. Negative derivative transformed melt curves from five *NAT2* gene polymorphisms 265 are shown in **Figure 3**. The assay detected all polymorphisms with 100% accuracy (average SD 266 in Tm across all probes = 0.34°C) compared with Sanger sequencing. The *NAT2* genotypes 267 corresponding to 20 blood samples covered all three categories - mutant, wild-type and 268 heterozygous for five *NAT2* positions except for NAT2-191 for which all samples were all wild-269 type. The 191G>A mutation is highly prevalent in African and African-American populations 270 and is less common in other populations (33). Among the 20 samples, predicted acetylator types 271 using the 5-SNP classifier were: 8 (40%) slow, 10 (50%) intermediate and 2 (10%) rapid 272 (**Supplementary Table 4a**).

- 274 We further assessed the analytic performance of the NAT2-PGx assay at lower sample volumes.
- 275 Our assay could accurately detect all melt peaks with as low as 25ul of sample volum**e**. The
- 276 variability in Tm from five *NAT2* probes for sample volumes 200ul-25ul is shown in **Figure 4**.
- 277 *NAT2* polymorphisms were accurately detected at all volumes (**Supplementary Table 4b)** and
- 278 demonstrated robustness to variation in input volume**.**

280 **DISCUSSION**

281 Despite availability of effective treatment for drug-sensitive tuberculosis, a substantial 282 proportion of population encounters drug associated toxicity or treatment failure, much of which 283 could be averted through dosing guided by genetic markers of drug metabolism (34). We 284 previously found that pharmacogenomic guided dosing of isoniazid could be highly cost-285 effective in low- and middle-income countries (35). A major barrier to its implementation has 286 been the lack of a simple, scalable assay that could be used at points of care where tuberculosis is 287 treated in resource-constrained settings. To address this gap, we used globally representative 288 genomic data to identify patterns of 5 SNPs that enable accurate prediction of isoniazid 289 acetylator phenotype, validating this with pharmacokinetic data of patients receiving tuberculosis 290 treatment. We then developed a prototype automated pharmacogenomic assay on the GeneXpert 291 platform, which is widely available globally but had never been applied to pharmacogenomics. 292 We found that this assay could robustly distinguish wild type, mutant and heterozygous alleles 293 from a range of blood volumes as low as 25 ul, making it suitable for use with venous blood 294 samples or finger-stick blood samples. The assay requires minimal hands-on time for sample 295 preparation, which would facilitate its use in resource-constrained settings.

296

297 An earlier model ("NAT2Pred") predicted NAT2 acetylation phenotype from unphased genomic 298 data; however, it had moderate error rates in distinguishing intermediate from rapid acetylators 299 (33). Moreover, error rates among individuals from Sub-Saharan Africa were 14%, in part due to 300 the exclusion of the G191A (R64Q) SNP, common to the NAT2 *14 allele cluster, which is 301 frequent in Africans and African-Americans, but virtually absent in Caucasian, Indian, and 302 Korean populations (36). A recent study using the set of 6 NAT2 SNPs included in NAT2Pred,

303 but not including G191A, found no correlation between *NAT2* genotype and INH acetylation 304 phenotype in HIV-infected, Zulu individuals with culture-confirmed tuberculosis in Durban, 305 South Africa (37), underscoring the importance of including this SNP in genotype predictions in 306 this region.

307

308 Indeed, ethnic differences in SNP frequencies are responsible for the differences in frequency of 309 rapid, intermediate and slow acetylator *NAT2* haplotypes (18, 23). We trained our SNP classifier 310 with globally representative data, which resulted in the selection and inclusion of the G191A 311 SNP in our model and assay. This is particularly important as Sub-Saharan Africa bears a 312 substantial burden of tuberculosis disease and mortality as well as HIV co-infection, which is 313 independently associated with greater pharmacokinetic variability and tuberculosis treatment 314 toxicity (38, 39).

315

316 The association between acetylation polymorphisms and INH metabolism was first demonstrated 317 in 1959, and their importance was well characterized in subsequent decades through phenotypic 318 descriptions (40-42). Subsequent genotypic descriptions confirmed that *NAT2* polymorphisms 319 predicted INH early bactericidal activity, and clinical outcomes including hepatotoxicity, relapse 320 and acquisition of drug resistance. Further dosing studies demonstrated that provision of lower 321 doses to slow acetylators and higher doses to rapid acetylators could achieve target 322 concentrations (43). One randomized trial of pharmacogenomic-guided dosing of INH during 323 active tuberculosis treatment found that it significantly reduced toxicities (among slow 324 acetylators) and treatment non-response (among rapid acetylators). Taken together, the evidence 325 for pharmacogenomic guided dosing to achieve consistent drug levels and improve clinical

326 outcomes is strong. Automated, easy-to-use assays could enable pharmacogenomic guided 327 isoniazid dosing in resource constrained settings, where a substantial burden of the world's 328 tuberculosis occurs.

329 The findings of this study are subject to several limitations. We tested the assays on 48 330 individuals with active tuberculosis and 20 healthy individuals with a diverse representation of 331 polymorphisms, but the number of participants with G191A mutations was limited (n=5). A 332 larger validation study involving testing on whole blood, including from finger stick capillary 333 blood, is needed to assess real-world performance of this assay under field conditions. Due to 334 unavailability of whole blood samples from TB patients, we used sputum samples to extract host 335 DNA for genotyping. Further studies should also investigate testing on non-invasive samples 336 including sputum, saliva or oral swabs, from which DNA is abundant. Second, we focused on 337 *NAT2* polymorphisms, as they explain majority of interindividual pharmacokinetic variability, 338 though polymorphisms in several other genes have been associated with hepatotoxicity. 339 However, these associations have been comparatively modest and somewhat inconsistent (44- 340 45). We focused on INH and did not include other important tuberculosis drugs, such as 341 rifampicin. The evidence base for pharmacogenomic markers predicting rifampin 342 pharmacokinetics is less robust, and findings concerning clinical outcomes such as toxicities or 343 treatment response are limited (46-49). However, given the importance of this drug class in 344 treatment of active and latent tuberculosis, and emerging evidence supporting greater efficacy of 345 higher doses of rifampin, further investigation of pharmacogenomic markers in rifampicin is 346 needed. Future assays may include polymorphisms influencing rifampicin metabolism to further 347 optimize treatment of tuberculosis.

349 Since the demonstration of the efficacy of six month, short-course chemotherapy in 1979, 350 standardized treatment for drug susceptible tuberculosis using weight-based doses has remained 351 essentially unchanged. Additionally, INH remains a major component of regimens for treatment 352 of latent tuberculosis, which is recommended by the WHO for young children, HIV-infected 353 individuals and household contacts of tuberculosis cases (50). More than half the world's 354 population have slow or rapid acetylation phenotypes, which put them at risk for excessive drug 355 levels resulting in drug toxicities or insufficient drug levels putting them at risk of acquired drug 356 resistance or disease relapse. Dose adjustment based on NAT2 acetylation genotyping can 357 achieve consistent, target drug levels and reduce the incidence of poor clinical outcomes. We 358 developed a prototype automated, cartridge-based assay that can reliably predict acetylation 359 phenotype directly from as low as 25 ul of whole blood. By developing this for the GeneXpert 360 platform, which is widely used in low- and middle-income countries for tuberculosis diagnosis, 361 this assay could make personalized tuberculosis treatment dosing available in resource-362 constrained settings. Further studies are needed to evaluate its accuracy and clinical impact in 363 real-world clinical settings.

364

365

366 **Funding**

367 FleXcartridges and technical support for their use were provided by Cepheid. This study was 368 supported by the Institute for Immunity, Transplantation, and Infection and the Department of 369 Medicine at Stanford University.

370

371 **Data availability**

- 372 Data supporting the findings of this manuscript are available in the Supplementary Information
- 373 files or from the corresponding author upon request.

375 **Acknowledgements**

376 We thank Veronique Dartois for performing the plasma drug level assays.

377

378 **Author contributions**

- 379 JRA and RV conceived of the study. RV, JC, and JRA designed the experiments. RV, SP,
- 380 FMM, MTV, ASS and JC collected data. RV, NZ, RS and JRA analyzed data. EW, DG and DP
- 381 provided technical guidance on the assay development. RV and JRA wrote the first draft of the
- 382 manuscript, and all authors contributed to the final version.

383 **Conflicts of Interest**

- 384 JRA and RV are named co-inventors on a provisional patent (Application number 62/991,477) for
- 385 a *NAT2* pharmacogenomic assay.

386 **References**

- 387 1. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F,
- 388 Phillips PP, Nunn AJ; REMoxTB Consortium. Four-month moxifloxacin-based regimens for
- 389 drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1577-87. doi:
- 390 10.1056/NEJMoa1407426. Epub 2014 Sep 7.
- 391 2. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye
- 392 E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis
- 393 C, Lapujade O, Olliaro PL, Lienhardt C; OFLOTUB/Gatifloxacin for Tuberculosis Project. A
- 394 four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014
- 395 Oct 23;371(17):1588-98. doi: 10.1056/NEJMoa1315817. Erratum in: N Engl J Med. 2015 396 Apr 23;372(17):1677.
- 397 3. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M,
- 398 Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L,
- 399 Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD,
- 400 Butcher PD, Mitchison DA; RIFAQUIN Trial Team. High-dose rifapentine with 401 moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1599-608.
- 402 4. Pratt VM, Everts RE, Aggarwal P, Beyer BN, Broeckel U, Epstein-Baak R, Hujsak P, 403 Kornreich R, Liao J, Lorier R, Scott SA, Smith CH, Toji LH, Turner A, Kalman LV. 404 Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes:
- 405 A GeT-RM Collaborative Project. J Mol Diagn. 2016 Jan;18(1):109-23.
- 406 5. García-Martín E. Interethnic and intraethnic variability of NAT2 single nucleotide 407 polymorphisms. Curr Drug Metab. 2008 Jul;9(6):487-97.

429 12. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. Isoniazid 430 bactericidal activity and resistance emergence: integrating pharmacodynamics and

- 431 pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents 432 Chemother. 2007 Jul;51(7):2329-36.
- 433 13. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug
- 434 concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013 Nov

435 1;208(9):1464-73.

- 436 14. Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current
- 437 standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.
- 438 Pharmacotherapy. 2009 Dec;29(12):1468-81
- 439 15. Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis
- 440 Infection: Recommendations from the National Tuberculosis Controllers Association and 441 CDC, 2020. MMWR Recomm Rep 2020;69(No. RR-1):1–11.
- 442 16. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M,
- 443 Cascorbi I, Doroshyenko O, Sörgel F, Fuhr U. Should we use N-acetyltransferase type 2 444 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005 445 May;49(5):1733-8.
- 446 17. Du H, Chen X, Fang Y, Yan O, Xu H, Li L, Li W, Huang W. Slow N-acetyltransferase 2
- 447 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol 448 Biol Rep. 2013 May;40
- 449 18. Sabbagh A, Langaney A, Darlu P, Gérard N, Krishnamoorthy R, Poloni ES. Worldwide 450 distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 451 2008 Feb 27;9:21.

471 Kamimura S, Fujio Y, Kawase I; Pharmacogenetics-based tuberculosis therapy research 472 group. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early 473 treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized

- 474 controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013 475 May;69(5):1091-101.
- 476 26. McInnes G and Russ A. Drug Response Pharmacogenetics for 200,000 UK Biobank 477 Participants.
- 478 27. *Database of arylamine N-acetyltransferases* (http://nat.mbg.duth.gr)
- 479 28. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F,
- 480 Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN,
- 481 Barry CE 3rd, Dartois V. The association between sterilizing activity and drug distribution
- 482 into tuberculosis lesions. Nat Med. 2015 Oct;21(10):1223-7.
- 483 29. Beal SL. Et al. NONMEM 7.4 Users Guides. (1989– 2019). ICON plc, Gaithersburg, MD. 484 https://nonmem.iconplc.com/nonmem744
- 485 30. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)--a Perl module for 486 NONMEM related programming. Comput Methods Programs Biomed. 2004 Aug;75(2):85- 487 94.
- 488 31. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and 489 proteins from cell and tissue samples. Biotechniques. 1993 Sep;15(3):532-4, 536-7. PMID: 490 7692896.
- 491 32. Kuznetsov IB, McDuffie M, Moslehi R. A web server for inferring the human N-492 acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype. Bioinformatics. 493 2009 May 1;25(9):1185-6.
- 494 33. Sabbagh A, Darlu P, Vidaud M. Evaluating NAT2PRED for inferring the individual 495 acetylation status from unphased genotype data. BMC Med Genet. 2009 Dec 31;10:148.

- 496 34. Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of 497 tuberculosis: a review. Pharmgenomics Pers Med. 2012;5:89-98
- 498 35. Rens NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, Croda J, Andrews JR. Cost-
- 499 effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of
- 500 Active Tuberculosis. Clin Infect Dis. 2020 Dec 15;71(12):3136-3143.
- 501 36. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2)
- 502 genetic diversity and traditional subsistence: a worldwide population survey. PLoS One. 503 2011 Apr 6;6(4):e18507.
- 504 37. Mthiyane T, Millard J, Adamson J, Balakrishna Y, Connolly C, Owen A, Rustomjee R,
- 505 Dheda K, McIlleron H, Pym AS. *N*-Acetyltransferase 2 Genotypes among Zulu-Speaking 506 South Africans and Isoniazid and *N*-Acetyl-Isoniazid Pharmacokinetics during 507 Antituberculosis Treatment. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02376-19.
- 508 38. van Oosterhout JJ, Dzinjalamala FK, Dimba A, Waterhouse D, Davies G, Zijlstra EE, 509 Molyneux ME, Molyneux EM, Ward S. Pharmacokinetics of Antituberculosis Drugs in 510 HIV-Positive and HIV-Negative Adults in Malawi. Antimicrob Agents Chemother. 2015
- 511 Oct; 59(10): 6175-80.
- 512 39. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. Variability in the 513 population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin 514 Pharmacol. 2011 Jul;72(1):51-62.
- 515 40. Iselius L, Evans DA. Formal genetics of isoniazid metabolism in man. Clin Pharmacokinet. 516 1983 Nov-Dec;8(6):541-4.
- 517 41. Evans DA. Genetic variations in the acetylation of isoniazid and other drugs. Ann N Y Acad 518 Sci. 1968 Jul 31;151(2):723-33.

- 519 42. Evans DA. An improved and simplified method of detecting the acetylator phenotype. J 520 Med Genet. 1969 Dec;6(4):405-7.
- 521 43. Naidoo A, Chirehwa M, Ramsuran V, McIlleron H, Naidoo K, Yende-Zuma N, Singh R,
- 522 Ncgapu S, Adamson J, Govender K, Denti P, Padayatchi N. Effects of genetic variability on
- 523 rifampicin and isoniazid pharmacokinetics in South African patients with recurrent
- 524 tuberculosis. Pharmacogenomics. 2019 Mar;20(4):225-240.
- 525 44. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the
- 526 population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J
- 527 Clin Pharmacol. 2006 Sep;62(9):727-35.
- 528 45. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1 529 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J 530 Tuberc Lung Dis. 2010 May;14(5):622-6.
- 531 46. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of 532 antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and 533 haplotype in pediatric patients. J Gastroenterol Hepatol. 2006 Apr;21(4):784-6.
- 534 47. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C,
- 535 Jaillon P. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine 536 hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
- 537 48. Strange RC, Jones PW, Fryer AA. Glutathione S-transferase: genetics and role in 538 toxicology. Toxicol Lett. 2000 Mar 15;112-113:357-63.
- 539 49. Mukonzo JK, Kengo A, Kutesa B, Nanzigu S, Pohanka A, McHugh TD, Zumla A, Aklillu
- 540 E. Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-

541 rifampicin sensitivity among Ugandan patients. Trans R Soc Trop Med Hyg. 2020 Feb 542 7;114(2):107-114.

543 50. Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr. 2017 Apr;5(2).

544

545 **Figure 1. Predicted** *NAT2* **phenotype from sputum samples and associated acetylation ratio** 546 **and isoniazid clearance rates from patients receiving tuberculosis treatment.** The (a) 8 hour 547 acetyl-INH to INH ratio and (b) isonazid clearance rates, according to acetylation phenotype 548 predicted from 5 SNPs, measured in sputum samples from 48 patients receiving treatment for 549 active tuberculosis.

550

551 **Figure 2. Schemata for the automated NAT2 Pharmacogenomic assay**. 1-2 drops of blood is 552 collected in an Eppendorf tube and mixed with lysis buffer to a total of 1 ml, which is then 553 loaded onto a GeneXpert Flex01 cartridge and placed into a GeneXpert instrument for automated 554 DNA extraction, qPCR and meltcurve analysis. Allele patterns for each of the 5 SNPs are 555 determined by Tm analysis, and the resulting data are used to predict acetylator phenotype.

556

557 **Figure 3. Negative derivative transformed melt curves for the five NAT2 gene** 558 **polymorphisms**. The shift in melt curve temperature is observed during a nucleotide exchange. 559 Molecular beacon probes are first hybridized and then melted off of their *NAT2* target amplicon. 560 The melt curves indicate wild type alleles at positions 191(red), 341(green) and 857 (orange); 561 and mutant alleles at positions 282(Blue) and 590(Purple).

562

563 **Figure 4. Effect of whole blood sample volume on melting temperature for wild type and** 564 **mutant alleles at 5 positions in** *NAT2***:** *NAT2* polymorphisms were accurately detected at all

- 565 volumes with sufficient different in melting temperature (Tm) to distinguish wild type from
- 566 mutant alleles. None of the individuals in this dataset had mutations at position 191.

Acetylation Genotype, n (%)

568 **Table 1. Summary of populations included in genomic analysis and their acetylation**

569 **genotypes.**

570

571

573 **Table 2. Out-of-sample prediction accuracy of unphased NAT2 SNP data for acetylation**

574 **phenotype in random forest models.** Models were trained with 5,738 individuals and tested on

575 2,823 individuals. Sens: sensitivity. Spec: specificity.

576

580

579

577

581 **Table 3. Melting temperature (Tm) values for five** *NAT2* **polymorphisms derived from**

582 **DNA-probe hybrid melts using single-plex assays validated on 48 pulmonary TB patients**

583

584 SD: Standard deviation, ΔTm: DNA-probe hybrid melting temperature difference, WT: Wild 585 type, MT: mutant

601 **At a Glance Commentary**

602 **Scientific Knowledge on the Subject:** Standardized weight-based dose of isoniazid (INH) may 603 result in variable drug levels in individuals leading to drug-induced toxicities, treatment failure 604 and relapse. Polymorphisms in the *NAT2* gene explain the majority of interindividual 605 pharmacokinetic variability of INH. Pharmacogenomic guided dosing may improve treatment 606 outcomes, but scalable assays are not available.

607 **What This Study Adds to the Field:** Earlier *NAT2* acetylation prediction algorithms had 608 diminished accuracy in African populations by failing to include a common polymorphism. We 609 developed an algorithm on globally representative data that predicted acetylation genotype with 610 100% accuracy using 5 unphased SNPs. We tested the accuracy of this acetylator prediction 611 algorithm against INH clearance rates in 48 pulmonary TB patients and found very strong high 612 correlation. We then developed a cartridge-based multiplex assay for these 5 SNPs on the 613 GeneXpert platform that can accurately detect *NAT2* genotype from 25ul whole blood. Because 614 this platform is widely used in low- and middle-income countries for tuberculosis diagnosis, this 615 assay could make personalized isoniazid dosing available in resource-constrained settings.

Sample collection

Collect 1-2 drops of whole blood (approx. 50ul)

4 Automated DNA (5) Data aquisition (6) **extraction & qPCR**

Total run time= 140min

Mix 950ul lysis buffer,

 at RT for 2min

 (2)

vortex for 2 sec and incubate

+

Whole blood

pretreatment

Load the cartridge in the GeneXpert machine and start the run

Acquire melt curve data for NAT2 gene polymorphism detection

Pipette 1ml pretreated sample and 70ul PCR mastermix into the cartridge

INH acetylator phenotype prediction

Upload NAT2 polymorphism data on phenotype prediction algorithm

Whole blood volume (ul)